DANAHER CORPORATION's ticker is DHR and the CUSIP is 235851102. A total of 1,200 filers reported holding DANAHER CORPORATION in Q1 2018. The put-call ratio across all filers is 0.54 and the average weighting 0.5%.
About DANAHER CORPORATION
Danaher Corporation is a global science and technology company that designs, manufactures, and markets innovative products and services to professional, medical, industrial, and commercial customers. The company operates through four segments: Life Sciences, Diagnostics, Dental, and Environmental & Applied Solutions.
Danaher's Life Sciences segment provides a range of research tools to scientists around the world, including mass spectrometry, chromatography, and automation systems. The Diagnostics segment offers a broad range of diagnostic products, including clinical chemistry, immunoassay, microbiology, and molecular diagnostic systems. The Dental segment provides a range of dental equipment and consumables, including imaging systems, dental instruments, and consumables. The Environmental & Applied Solutions segment offers a range of products and services to help customers protect the environment and improve productivity.
Danaher has a strong track record of growth and innovation, driven by its focus on continuous improvement and customer satisfaction. The company has a culture of operational excellence, which has enabled it to consistently deliver high-quality products and services to its customers. Danaher's management team is highly experienced and has a proven track record of creating value for shareholders.
In conclusion, Danaher Corporation is a well-established and innovative company that is well-positioned to continue delivering strong growth and value to its shareholders. With its focus on operational excellence and customer satisfaction, Danaher is a company that investors should keep an eye on.
It's important to note that this information is for educational purposes only and has not been fact-checked. As with any investment, it's important to do your own research and consult with a financial advisor before making any investment decisions.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $909,422,956 | +17.5% | 3,665,550 | +13.6% | 0.32% | +19.0% |
| Q2 2023 | $774,211,440 | +93043.6% | 3,225,881 | -2.2% | 0.27% | -12.9% |
| Q1 2023 | $831,202 | -3.8% | 3,297,900 | +1.3% | 0.31% | -7.8% |
| Q4 2022 | $863,930 | -99.9% | 3,254,953 | -22.0% | 0.34% | -23.2% |
| Q3 2022 | $1,077,341,000 | +10.6% | 4,171,053 | +8.5% | 0.44% | +15.6% |
| Q2 2022 | $974,252,000 | -14.9% | 3,842,902 | -2.9% | 0.38% | +1.6% |
| Q1 2022 | $1,144,623,000 | -2.3% | 3,956,934 | +11.1% | 0.37% | +6.9% |
| Q4 2021 | $1,171,422,000 | +2.6% | 3,560,445 | -5.4% | 0.35% | -1.1% |
| Q3 2021 | $1,141,254,000 | +9.0% | 3,765,181 | -3.5% | 0.35% | +12.5% |
| Q2 2021 | $1,047,149,000 | +42.4% | 3,902,029 | +19.5% | 0.31% | +33.3% |
| Q1 2021 | $735,128,000 | +0.8% | 3,266,072 | -0.5% | 0.23% | -5.3% |
| Q4 2020 | $729,362,000 | -1.0% | 3,283,344 | -4.1% | 0.25% | -12.7% |
| Q3 2020 | $736,864,000 | +16.1% | 3,422,022 | -4.7% | 0.28% | +9.7% |
| Q2 2020 | $634,772,000 | +17.7% | 3,589,728 | -8.5% | 0.26% | -1.9% |
| Q1 2020 | $539,177,000 | -3.0% | 3,923,083 | +8.3% | 0.26% | +24.6% |
| Q4 2019 | $555,787,000 | +4.0% | 3,621,231 | -2.2% | 0.21% | -2.3% |
| Q3 2019 | $534,514,000 | +2.0% | 3,700,851 | +1.0% | 0.22% | +4.9% |
| Q2 2019 | $523,790,000 | +11758.5% | 3,664,924 | +10853.5% | 0.21% | +758.3% |
| Q1 2019 | $4,417,000 | +29.3% | 33,459 | +1.0% | 0.02% | +9.1% |
| Q4 2018 | $3,415,000 | -1.6% | 33,116 | +3.6% | 0.02% | +22.2% |
| Q3 2018 | $3,472,000 | +16.8% | 31,957 | +6.1% | 0.02% | -5.3% |
| Q2 2018 | $2,973,000 | +0.8% | 30,132 | 0.0% | 0.02% | 0.0% |
| Q1 2018 | $2,950,000 | +5.4% | 30,132 | -0.1% | 0.02% | +5.6% |
| Q4 2017 | $2,798,000 | +20.1% | 30,149 | +11.0% | 0.02% | +20.0% |
| Q3 2017 | $2,329,000 | -7.9% | 27,153 | -9.3% | 0.02% | -6.2% |
| Q2 2017 | $2,528,000 | -35.6% | 29,953 | -34.7% | 0.02% | -30.4% |
| Q1 2017 | $3,924,000 | +1.0% | 45,875 | -8.1% | 0.02% | +15.0% |
| Q4 2016 | $3,885,000 | -9.0% | 49,913 | -8.4% | 0.02% | -20.0% |
| Q3 2016 | $4,271,000 | -22.5% | 54,481 | -0.1% | 0.02% | -26.5% |
| Q2 2016 | $5,510,000 | +9.0% | 54,554 | +2.3% | 0.03% | +30.8% |
| Q1 2016 | $5,057,000 | +2.3% | 53,306 | +0.2% | 0.03% | +4.0% |
| Q4 2015 | $4,944,000 | -64.4% | 53,226 | -67.4% | 0.02% | -68.4% |
| Q3 2015 | $13,894,000 | +8.2% | 163,050 | +8.7% | 0.08% | +14.5% |
| Q2 2015 | $12,838,000 | +0.3% | 149,993 | -0.5% | 0.07% | -1.4% |
| Q1 2015 | $12,797,000 | -45.9% | 150,734 | -45.4% | 0.07% | -47.4% |
| Q4 2014 | $23,656,000 | +8.9% | 276,005 | -3.4% | 0.13% | -0.7% |
| Q3 2014 | $21,716,000 | -26.1% | 285,812 | -23.4% | 0.13% | -25.1% |
| Q2 2014 | $29,367,000 | -2.3% | 373,010 | -6.9% | 0.18% | -0.6% |
| Q1 2014 | $30,065,000 | -7.7% | 400,861 | -5.0% | 0.18% | -14.3% |
| Q4 2013 | $32,574,000 | +7.0% | 421,943 | -3.9% | 0.21% | +6.6% |
| Q3 2013 | $30,436,000 | +5.9% | 439,062 | -3.3% | 0.20% | +2.1% |
| Q2 2013 | $28,735,000 | – | 453,948 | – | 0.19% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| ARTHUR M. COHEN & ASSOCIATES, LLC | 217,436 | $53,823,432 | 13.80% |
| Defender Capital, LLC. | 152,962 | $37,949,802 | 13.74% |
| Bancreek Capital Management, LP | 60,890 | $15,106,809 | 13.58% |
| BOONE CAPITAL MANAGEMENT LLC | 129,163 | $32,045,340 | 10.11% |
| Eagle Health Investments LP | 175,085 | $43,438,589 | 9.57% |
| Third Point | 2,450,000 | $607,845,000 | 9.22% |
| Clio Asset Management LLC | 41,695 | $10,344,530 | 9.04% |
| Consulta Ltd | 500,000 | $124,050,000 | 8.91% |
| Riverstone Advisors, LLC | 47,960 | $11,799,701 | 8.16% |
| CADEN CAPITAL PARTNERS, LP | 123,755 | $27,215,377 | 7.66% |